Leo Pharma absorbs scrapped innovation hubs to streamline focus

Leo Pharma’s decision to integrate three previously external innovation hubs in Boston, Tokyo and Shanghai stems from a wish to bring activities closer to its own R&D division. According to Head of R&D Jörg Möller, the company is now only betting in areas where it has a competitive edge and can win.

Leo Pharma's head of research and development, Jörg Möller, will still have to keep track of three development hubs across the US and Asia, despite the organization at large refocusing its internal R&D | Photo: MAGNUS MØLLER

Leo Pharma previously reported that its three external innovations hubs were to close, but this isn’t entirely the case. Going forward, the units will become part of Leo Pharma’s internal research organization, according to Jörg Möller, head of global research and development at Leo Pharma.

”We have moved them to a different organizational setup. We had a stand-alone science hub organization which reported to me that we have closed, but we have moved the activities to our research and development functions,” he explains to MedWatch.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs